Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma

NCT01134614 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01134614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01134614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 28, 2010
Completion date
March 19, 2027
Enrollment
245 (actual)
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma, recurrent melanoma, stage iii cutaneous melanoma ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, unresectable melanoma